![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1406022
¼ö¾× ¹é : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)IV Bags - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029 |
¼ö¾× ¹é ½ÃÀåÀº ¿¹Ãø ±â°£ Áß 5.3%ÀÇ CAGR·Î ÃßÀÌÇÒ Àü¸ÁÀÔ´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº ¼ö¾× ¹éÀÇ ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÆÒµ¥¹Í ±â°£ Áß Äڷγª¹ÙÀÌ·¯½º °¨¿° ȯÀÚ Áõ°¡¿Í ÀÔ¿øÀ² Áõ°¡·Î ÀÎÇØ ¼ö¾× ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù Nutrients Àú³Î¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é °í¿ë·® ºñŸ¹Î C ¼ö¾× ¿ä¹ýÀº Àå±âÀûÀÎ COVID-19 ȯÀÚÀÇ ¼ö¸éÀå¾Ö, ÁýÁß·Â ÀúÇÏ¿Í °°Àº ÇÇ·Î ¹× ÇÇ·Î °ü·Ã Áõ»óÀ» »ó´çÈ÷ °³¼±ÇÏ´Â °ÍÀ¸·Î °üÂûµÇ¾ú½À´Ï´Ù. ȯÀÚÀÇ Ã¼³»¿¡ ºñŸ¹ÎC¸¦ Åõ¿©Çϸé ȸº¹ÀÌ »¡¶óÁö±â ¶§¹®¿¡ ºñŸ¹ÎC Á¤¸ÆÁÖ»ç ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁ³½À´Ï´Ù. µû¶ó¼ ÆÒµ¥¹Í ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦°¡ ÇØÁ¦µÇ°í Ä¡·á ¼ºñ½º°¡ Àç°³µÊ¿¡ µû¶ó ¸¸¼ºÁúȯÀ¸·Î º´¿øÀ» ã´Â »ç¶÷µéÀÌ Áõ°¡ÇÏ¸é¼ ¼ö¾× Åõ¿©¸¦ À§ÇÑ ¼ö¾× ¹é¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çß½À´Ï´Ù. µû¶ó¼ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¼ö¼ú ¹× ±³Åë»ç°í Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡ µîÀÇ ¿äÀÎÀÌ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À§Àå Áúȯ, ¾Ï, ½Å°æ Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ´Â °ÍÀº ½ÃÀå¿¡¼ ¼ö¾× ÁÖ¸Ó´Ï¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 7¿ù¿¡ ¹ßÇ¥µÈ ±¹¸³º¸°Ç¿ø ÀÚ·á¿¡ µû¸£¸é ºÏ¹Ì¿Í À¯·´À» Æ÷ÇÔÇÑ À¯·´°ú ¹Ì±¹ Áö¿ªÀÇ À§½Äµµ¿ª·ùÁúȯ(GERD) À¯º´·üÀº 2022³â ±âÁØ ¾à 20%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ÀÌ ÀÚ·á¿¡ µû¸£¸é 2022³â ¹Ì±¹ÀÇ GERD À¯º´·üÀº 18.1%¿¡¼ 27.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.
¶ÇÇÑ 'Cancer Facts and Figures 2023' º¸°í¼¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼ 297,790¸íÀÇ ¿©¼ºÀÌ Ä§À±¼º À¯¹æ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³â¿¡´Â 287,850¸íÀÇ ¿©¼ºÀÌ »õ·Î À¯¹æ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº ÀÚ·á¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â 2023³â¿¡ ¾à 55,720¸íÀÇ ¿©¼ºÀÌ ºñħÀ±¼º(in situ) À¯¹æ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³â¿¡´Â 51,400¸íÀÌ Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¾Ï Ä¡·á´Â ÀÎüÀÇ ¿µ¾çÀ» »©¾Ñ¾Æ ±Ë¾ç, À§Àå ±â´É Àå¾Ö, ½ÅüÀû ¸·ÈûÀ» À¯¹ßÇÏ¿© ½Åü¿¡ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ Á¤¸ÆÁÖ»ç ¹é¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̴ ȯÀÚ¿¡°Ô ºñ°æ±¸ ¿µ¾ç °ø±Þ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
¶ÇÇÑ ±³Åë»ç°í¿Í ¼ö¼ú ºÎ´ã Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 6¿ù¿¡ ¹ßÇ¥µÈ StatBelÀÇ Åë°è¿¡ µû¸£¸é 2022³â 37,643°ÇÀÇ ±³Åë»ç°í°¡ ¹ß»ýÇÏ¿© 2021³â 34,640°ÇÀÇ ±³Åë»ç°í¿¡ ºñÇØ º§±â¿¡¿¡¼ °æ»óÀÚ 42,134¸í, Áß»óÀÚ 3,400¸í µî ÃÑ 46,074¸íÀÇ »ç»óÀÚ°¡ ¹ß»ýÇß´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ µ¶ÀÏ ½ÉÀå ¼ö¼ú º¸°í¼ 2022³âÆÇ¿¡¼ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é µ¶ÀÏ¿¡¼´Â 2022³â¿¡ ¾à 356°ÇÀÇ ´Üµ¶ ½ÉÀå À̽Ä, 228°ÇÀÇ ´Üµ¶ Æó À̽Ä, 5°ÇÀÇ ½ÉÆó º¹ÇÕ À̽ÄÀÌ ÀÌ·ç¾îÁ³°í, 2021³â¿¡´Â 329°ÇÀÇ ´Üµ¶ ½ÉÀå À̽Ä, 254°ÇÀÇ ´Üµ¶ Æó À̽Ä, 1°ÇÀÇ ½ÉÆó º¹ÇÕ À̽ÄÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. ÀÌó·³ »ç°í¿Í ¼ö¼ú Áõ°¡·Î ÀÎÇØ ¼ö¾× Åõ¿©°¡ ÇÊ¿äÇØÁö¸é¼ ½ÃÀå ¼ºÀåÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ Á¦Ç° Ãâ½Ã°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡¼ ´Ù¾çÇÑ À¯ÇüÀÇ ¼ö¾× ¹éÀÇ °¡¿ë¼ºÀÌ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 3¿ù, Fagron Sterile Services(FSS)´Â Á¤¸Æ ³»(IV) ¹é¿¡¼ »ç¿ëÇÒ ¼öÀÖ´Â ÆæÅ¸´Ò, ÇÏÀ̵å·Î ¸ð¸£ Æú·Ð, ¹Ì´Ù Á¹¶÷ÀÇ ¿©·¯ ÇÁ·¹Á¨Å×À̼ÇÀ» °®Ãá »õ·Î¿î Ç÷§ÆûÀ» ¹ßÇ¥Çß½À´Ï´Ù, ³ë¸£¿¡Çdz×ÇÁ¸°, ¹ÝÄÚ¸¶À̽Å, ÄÉŸ¹Î, Æä´Ò¿¡ÇÁ¸° µî ´Ù¸¥ ¼ö¾× ¹é¿ë ¾à¹°µµ Á¦Ç° Æ÷Æ®Æú¸®¿À¿¡ Ãß°¡ÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
µû¶ó¼ ¼Òȱâ Áúȯ, ±³Åë»ç°í, ¼ö¼ú, Á¦Ç° Ãâ½Ã µîÀÇ ºÎ´ã Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÇÃ¶ó½ºÆ½ ¼ö¾× ¹é¿¡¼ ÈÇй°ÁúÀÌ ¿ëÃâµÉ À§ÇèÀº ¿¹Ãø ±â°£ Áß ¼ö¾× ¹é ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
Æú¸®ÇÁ·ÎÇÊ·»Àº Áõ±â ¸ê±Õ ÀÇ·á±â±â°¡ ÇÊ¿äÇÑ °æ¿ì »ç¿ëµÇ´Â ºñ¿ë È¿À²ÀûÀÎ ÀÇ·á¿ë ÇÃ¶ó½ºÆ½ ¼ÒÀçÀÔ´Ï´Ù. Æú¸®ÇÁ·ÎÇÊ·»Àº Áõ±â ¸ê±Õ¿¡ ´ëÇÑ ³»¼º, ¿©·¯ ¹ø Àç»ç¿ëÇÒ ¼ö ÀÖ´Â ³»±¸¼º, ´Ù¸¥ Àç·áº¸´Ù ¿ì¼öÇÑ ÀçȰ¿ë¼º µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ¼ö¾× ¹é Á¦Á¶¿ë ÀÇ·á¿ë ÇÃ¶ó½ºÆ½À¸·Î ¸Å·ÂÀûÀÔ´Ï´Ù.
Æú¸®ÇÁ·ÎÇÊ·» ¼ö¾× ¹é¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ Æú¸®ÇÁ·ÎÇÊ·» ¼ö¾× ¹é ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ Æú¸®ÇÁ·ÎÇÊ·» ¼ö¾× ¹éÀº »ó´ëÀûÀ¸·Î Àú·ÅÇÑ °¡°Ý, ¹Ý°áÁ¤Áú·Î ÀÎÇÑ ³ôÀº ±ÁÈû °µµ, ³»½À¼º, ³»ÇǷμº µî ´Ù¸¥ ¼ö¾× ¹é¿¡ ºñÇØ ¿ì¼öÇÑ Æ¯¼ºÀ» °¡Áö°í ÀÖÀ¸¸ç, ¼ö¾× Åõ¿© ¹× º¸°ü¿¡ ÀûÇÕÇÕ´Ï´Ù. µû¶ó¼ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ °íǰÁú ¼ö¾× ¹é °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ±â¾÷ÀÌ Áõ°¡Çϰí ÀÖ´Â Á¡µµ ¿¹Ãø ±â°£ Áß ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù Gufic Biosciences´Â Å»Âø½Ä ¾Ë·ç¹Ì´½ Æ÷ÀÏÀ» °®Ãá °íǰÁú µà¾ó è¹ö Æú¸®ÇÁ·ÎÇÊ·»(DEHP ÇÁ¸®) ¹éÀ» Ãâ½ÃÇß½À´Ï´Ù. À̸¦ ÅëÇØ ȯÀÚ¿¡°Ô Åõ¿©Çϱâ Á÷Àü¿¡ À籸¼ºÇØ¾ß ÇÏ´Â ºÒ¾ÈÁ¤ÇÑ ¾à¹°À» º¸°üÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2022³â 1¿ù, ICU MedicalÀº Smiths Group plc·ÎºÎÅÍ Smiths MedicalÀ» ÀμöÇß½À´Ï´Ù. ½º¹Ì½º ¸ÞµðÄÃÀÇ ÁÖ»ç±â, ¿Ü·¡¿ë ¼ö¾× Àåºñ, ¹Ù½ºÅ§·¯ ¾×¼¼½º ¹× ¹ÙÀÌÅ»Äɾî Á¦Ç°µéÀÌ ICU ¸ÞµðÄÃÀÇ Æ÷Æ®Æú¸®¿À¿¡ Ãß°¡µÇ¾î ´õ¿í °ß°íÇÑ ¼¼°è ¼ö¾× Ä¡·á ¼±µµ±â¾÷ÀÌ Åº»ýÇß½À´Ï´Ù.
µû¶ó¼ Æú¸®ÇÁ·ÎÇÊ·» °¡¹æÀÇ ¿ìÀ§¿Í Á¦Ç° Ãâ½Ã µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ Áß ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ ¼ö¾× ¹é ½ÃÀå¿¡¼ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Ä¡·á ¹× ¾ÈÀü¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Á¤Ã¥, ÀÌ Áö¿ªÀÇ Á¦Ç° Ãâ½Ã Áõ°¡µµ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Àα¸ÀÇ ¾Ï ¹ßº´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á´Â ÀÎüÀÇ ¿µ¾çÀ» »©¾Ñ¾Æ ±Ë¾ç, À§Àå ±â´É Àå¾Ö ¹× ½ÅüÀû Àå¾Ö¸¦ À¯¹ßÇÏ¿© ½Åü¿¡ ¿µÇâÀ» ¹ÌÄ¡¹Ç·Î ȯÀÚ¿¡°Ô ºñ°æ±¸ ¿µ¾çÁ¦¸¦ Åõ¿©ÇØ¾ß ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ¾ÏÇùȸ°¡ ¹ßÇ¥ÇÑ 2023³â Åë°è¿¡ µû¸£¸é 2022³â ¹Ì±¹¿¡¼ 191¸¸ 8030¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÈ ¹Ý¸é, 2023³â¿¡´Â ¾à 195¸¸ 8310¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ ¾Ï ȯÀÚ Áõ°¡°¡ ¿¹»óµÊ¿¡ µû¶ó ȯÀÚ¿¡°Ô ¹«±Õ ºñ°æ±¸ ¼ö¾×À» Åõ¿©Çϱâ À§ÇÑ ¼ö¾× ¹é¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¶ÇÇÑ Àå±â ÀÌ½Ä ¼ö¼úÀº Ç÷°ü³» ºÎÇÇ À¯Áö¿Í ½ÅÀå À̽ÄÀÇ ÃæºÐÇÑ °ü·ù¸¦ À§ÇØ ÀÌ½Ä ¼ö¼ú Áß°ú ¼ö¼ú ÈÄ Á¤¸ÆÁÖÀÔÀÇ Çʿ伺ÀÌ Áõ°¡ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î IroDat°¡ ¹ßÇ¥ÇÑ 2023³â µ¥ÀÌÅÍ¿¡ µû¸£¸é 2022³â ¹Ì±¹¿¡¼´Â ¾à 5,862°ÇÀÇ ½ÅÀå ÀÌ½Ä ¼ö¼úÀÌ ±â·ÏµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ À§ÀÇ ÀÚ·á¿¡ µû¸£¸é 2021³â¿¡´Â 1,974°ÇÀÇ ½ÅÀå ÀÌ½Ä ¼ö¼úÀÌ ÀÌ·ç¾îÁ³°í, 2022³â¿¡´Â ¸ß½ÃÄÚ¿¡¼ ¾à 2,713°ÇÀÇ ½ÅÀå ÀÌ½Ä ¼ö¼úÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. µû¶ó¼ ÀÌ Áö¿ªÀÇ ÀÌ½Ä ¼ö¼ú °Ç¼ö Áõ°¡´Â ¼ö¾× Åõ¿©¿ë ¼ö¾× ¹é¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ ÀÌ Áö¿ª¿¡¼ÀÇ Á¦Ç° ½ÂÀÎ ¹× Ãâ½Ã Áõ°¡´Â ÀÌ ½ÃÀå¿¡¼ ¼ö¾× ¹éÀÇ °¡¿ë¼ºÀ» ³ô¿© ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 2¿ù B. Braun MedicalÀº ¹Ì±¹ FDA·ÎºÎÅÍ Ç÷θ®´Ù ÁÖ µ¥ÀÌÅ䳪 ºñÄ¡¿¡ À§Ä¡ÇÑ »õ·Î¿î ¼ö¾× Á¦Á¶ ½Ã¼³ÀÇ °¡µ¿ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ½Ã¼³Àº ¼ö¾× ºÎÁ·À» ÇØ°áÇϱâ À§ÇØ ¹Ì±¹³» Á¦Á¶ ¹× °ø±Þ¸Á¿¡ 10¾ï ´Þ·¯¸¦ ÅõÀÚÇÏ¿© 0.9%ÀÇ ¿°È³ªÆ®·ýÀ» »ý»êÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ ¾Ï ºÎ´ã Áõ°¡, ½ÅÀå ÀÌ½Ä ¼ö¼ú Áõ°¡, Á¦Ç° ½ÂÀÎ µîÀÇ ¿äÀÎÀÌ ¿¹Ãø ±â°£ Áß ¼ö¾× ¹é ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼ö¾× ¹é ½ÃÀåÀº Àû´çÇÑ °æÀïÀÌ ÀÖÀ¸¸ç, º¹¼öÀÇ ´ë±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ±â¾÷¿¡´Â Baxter International Inc., Technoflex, Sippex IV bag, Polycine GmbH, ICU Medical Inc., B. Braun Medical Inc. µîÀÌ ÀÖ½À´Ï´Ù.
The IV bags market is expected to register a CAGR of 5.3% over the forecast period.
The COVID-19 pandemic significantly impacted the growth of IV bags. The demand for IV infusion therapy increased due to the rise in patients with coronavirus infections and higher hospitalization rates during the pandemic. For instance, according to an article published in Nutrients in June 2022, it was observed that high-dose IV vitamin C therapy considerably improves exhaustion and fatigue-related symptoms such as sleep problems and loss of focus in long-term COVID-19 patients. It increased the demand for vitamin C IV infusion as administering Vitamin C to the patient's body expedites their recovery. It, thus, impacted the market growth during the pandemic. Moreover, with the released restrictions and resumed treatment services, the number of people visiting hospitals due to chronic diseases increased, further fueling the demand for IV bags for administering fluids. Thus, the studied market is expected to grow significantly over the forecast period.
Factors such as the increasing prevalence of chronic diseases, the growing number of surgeries and road accidents, and the rising geriatric population are expected to boost the market growth over the forecast period.
The increasing burden of chronic diseases such as gastrointestinal diseases, cancer, and neurological diseases is the key factor driving the demand for IV bags in the market. For instance, as per the data from the National Institute of Health published in July 2022, the prevalence of gastroesophageal reflux disease (GERD) in western regions, including North America and Europe, is around 20% as of 2022. Moreover, as per the same source, in the United States, the prevalence of GERD was between 18.1% to 27.8% in 2022.
Additionally, according to the statistics published in the Cancer Facts and Figures 2023 report, in the United States, 297,790 women are expected to be diagnosed with invasive breast cancer in 2023, compared to 287,850 new cases in 2022. Also, according to the same source, in 2023, about 55,720 women are expected to be diagnosed with non-invasive (in situ) breast cancer in the United States, compared to 51,400 cases in 2022. It is expected to increase the demand for IV bags as cancer treatment deprives the human body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages. It fuels the demand for delivering parenteral nutrition to patients, propelling market growth.
Furthermore, the increasing burden of road accidents and surgical procedures is expected to drive market growth. For instance, as per the StatBel statistics published in June 2023, there were 37,643 road traffic accidents in 2022, bringing the total of casualties to 46,074, including 42,134 slightly injured and 3,400 seriously injured in Belgium as compared to 34,640 road traffic accidents in 2021. Also, as per the data published by German Heart Surgery Report 2022, about 356 isolated heart transplantations, 228 isolated lung transplantations, and 5 combined heart-lung transplantations were performed in 2022 in Germany as compared to 329 isolated heart transplantations, 254 isolated lung transplantations, and one combined heart-lung transplantations were performed in 2021. Thus, the increasing number of accidents and surgeries necessitate fluid administration, which is expected to increase market growth.
Moreover, the rising product launches increase the availability of different types of IV bags in the market, which is expected to contribute to market growth. For instance, in March 2021, Fagron Sterile Services (FSS) introduced a new platform with multiple presentations of fentaNYL, HYDROmorphone, and midazolam, available for Intravenous (IV) Bags. FSS planned to add other IV Bag medications, such as oxytocin, NORepinephrine, Vancomycin, Ketamine, and PHENYLephrine, into its product portfolio.
Therefore, the studied market is anticipated to grow over the forecast period due to the rising burden of gastrointestinal diseases, road accidents, surgeries, and product launches. However, the risk of leaching chemicals from plastic IV bags will likely hinder the growth of the IV bags market over the forecast period.
Polypropylene is a cost-effective medical-grade plastic material used where steam-sterilized medical devices are necessary. The advantages offered by polypropylene, such as resistance to steam sterilization and durability due to which it can be reused for several cycles, as well as its recyclability over other materials, make it an attractive medical-grade plastic for manufacturing IV bags.
The polypropylene IV bags segment is expected to witness significant growth over the forecast period owing to the increasing demand for polypropylene bags and the rising burden of chronic diseases. In addition, the advantages offered by polypropylene IV bags, such as being relatively inexpensive and possessing high flexural strength because of their semi-crystalline nature, moisture resistance, and good fatigue resistance, over other IV bags make it a more preferred choice for administering and storing IV fluids. Hence, it is expected to augment the segment growth.
Furthermore, the increasing focus of the companies to develop high-quality IV bags is anticipated to fuel the segment growth over the forecast period. For instance, in June 2022, Gufic Biosciences launched high-quality dual chamber polypropylene (DEHP free) bags with peelable aluminum foil. It allows the storage of unstable drugs, which need reconstitution just before administration to the patient. Also, in January 2022, ICU Medical acquired Smiths Medical from Smiths Group plc. The acquisition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products to the ICU Medical portfolio created a leading infusion therapy company with a more robust global reach.
Therefore, the studied market is expected to grow over the forecast period due to factors such as the polypropylene bags' advantages and product launches.
North America is expected to hold a significant market share in the IV bags market due to the increasing prevalence of chronic diseases, growing geriatric population, and rising healthcare spending. In addition, stringent regulations and policies towards patient care and safety and rising product launches in the region are also expected to boost the market growth over the forecast period.
The increasing burden of cancer among the population is the key factor driving the market growth. Cancer treatment deprives the human body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages, necessitating the administration of parenteral nutrition to patients. For instance, according to 2023 statistics published by the American Cancer Society, about 19,58,310 new cancer cases are expected to be diagnosed in the United States in 2023, compared to 1,918,030 cases in 2022. Thus, the expected increase in cancer patients raises the demand for IV bags to administer sterile parenteral fluids to patients, propelling the market growth.
Additionally, organ transplantation procedures increase the need for infusing intravenous fluids during and after transplant surgery for the maintenance of intravascular volume and adequate perfusion of the kidney transplant. For instance, according to the 2023 data published by IroDat, about 5,862 kidney transplant procedures were recorded in the United States in 2022. Also, as per the above source, about 2,713 kidney transplant procedures were performed in Mexico in 2022, compared to 1,974 kidney transplants in 2021. Thus, the increasing number of transplant procedures in the region is expected to fuel the demand for IV bags for administering fluids, propelling the market growth.
Furthermore, the increasing product approvals and launches in the region are also expected to increase the availability of IV bags in the market, hence contributing to market growth. For instance, in February 2022, B. Braun Medical received the US FDA approval to begin operations at its new IV saline solution manufacturing facility in Daytona Beach, Florida. The facility spent USD 1 billion on its US manufacturing and supply chain to address shortages of IV fluids and is anticipated to produce 0.9% sodium chloride for injection.
Therefore, factors such as the rising burden of cancer, increasing kidney transplant procedures, and product approvals are expected to propel the growth of the IV bags market over the forecast period.
The IV Bags market is moderately competitive and consists of several major players. Some companies currently dominating the market are Baxter International Inc., Technoflex, Sippex IV bag, Polycine GmbH, ICU Medical Inc., and B. Braun Medical Inc., among others.